Since the start of the Covid 19 pandemic, all the experts on the planet have been looking for a solution to this problem. There are currently more than 1.2 million deaths worldwide and more than 47 million people infected.
“Treatments will be as much if not more important than a vaccine“
Despite some progress in vaccines, many experts agree that treatments will be as much if not more important than a vaccine and all investors must know this company.
CSE : RVV | OTC : RVVTF
Revive Therapeutics is currently one of the few in the U.S. Food & Drug Administration (“U.S. FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.
Recently, the Company has committed to ten clinical sites across Florida, Texas, Nevada, Arizona and California, and it is estimated that over 200 patients will have completed the Study for the interim analysis by the end of December 2020.
The recent publication of the potential of N-acetyl-cysteine (“NAC”) in the treatment of COVID-191 serves as further validation for Bucillamine. NAC has been shown to significantly attenuate clinical symptoms in viral infections in animals and humans, primarily via donation of thiols to increase antioxidant activity of cellular glutathione.
In comparison, Bucillamine, with its well-established safety record in over 30 years of use in the treatment of rheumatoid arthritis, has been shown to be 16 times more potent as a thiol donor in vivo than NAC.
Michael Frank, Revive’s Chief Executive Officer is confident of the outcome of the study:
“We are one of a few life sciences companies evaluating an investigational drug in a Phase 3 clinical trial for COVID-19 and with the rising prevalence of cases throughout the US, we are confident that our targets will be achieved to support the potential FDA approval and commercialization of Bucillamine for the treatment of the virus, ”
With a market value of less than $50 million, Revive Therapeutics is the most underrated company currently in phase 3 with a clinical study underway.
Market Capitalization for Phase 3 COVID Drug Trials (treatment)
|Company||Symbol||Shares Out||Market Cap|
|Relief Therapeutics||RLFTF||2.25 B||912M|
|Eli Lilly & Co.||LLY||956.5M||135.16B|
All this with a booming psychedelics sector in which Revive Therapeutics is very well positioned.
Revive Therapeutics announced in early September a clinical study entitled, “Phase I Study of the Safety and Feasibility of Psilocybin in Adults with Methamphetamine Use Disorder“ with the Board of Regents of the University of Wisconsin System (UWS).
In addition, under its sponsored research partnership with the Reed Research Group out of the University of Wisconsin-Madison, the Company is developing its tannin-chitosan composite of orally dissolvable thin films which offers a unique delivery platform for therapeutic doses (1-20mg) of psilocybin into the oral cavity.
Revive Therapeutics products pipeline
With a market of more than 100B in value according to report from Cannacord firm and companies like Compass Pathways with a value of more than 1.25B, Revive Therapeutics is a bargain that investors will not be able to ignore for long.
PSYCHEDELIC MARKET VALUE
For more information on Revive Therapeutics:
Sign up for MORE news updates !
This article is written and published by The Cannabis Stock
Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies
The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.
Disclosure : Revive Therapeutics are a client of The Cannabis Stock.